Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
Conditions: Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation; Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation; Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Infiltr ating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Metastatic Urothelial Carcinoma; MTAP Negative Interventions: Drug: Avelumab; Drug: Pemetrexed Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Micropapillary Carcinoma | Research